feasibility and newly implementation acquired, of EGFR archive tissue mutation testing or either in routine clinical practice; 39 Spanish centres using two central testing centres and 7 on-site testing facilities Tao 2011 Conference Canada EGFR mutation Result from pilot 1869 requests March 2010 – Not specified Reviewed, Test failures testing in routine testing archive FFPE abstract Nov 2010 TATRS advanced network NSCLC includes tissue TATRR involving 5 and cytology NSCLC testing samples laboratories Full journal EGFR mutation Study of the Year 1: 152 Screening Year 1: Blocks or Leary 2012 UK Test failures article testing in feasibility of samples (144 period: Jan TheraScreen slides; not TATO advanced prospective cases) 2009 - Jan EGFR29 ARMS specified TATRS EGFR testing in 2010; Jan mutation kit; whether Year 2: 755 routine clinical 2010 - Jan testing was on NSCLC cases Year 2: practice; single 2011 newly Combination of testing centre acquired, ARMS; fragment archive tissue analysis; direct or either; some sequencing samples were from external sources Conference EGFR and ALK Retrospective 63 prior to policy; 6 months FFPE archival US Not specified TATO 2012 abstract mutation testing observation 123 post before and 6 tissue used in NSCLC study to months after determine the introduction of utility of a reflex reflex policy testing policy for the mutations:
feasibility and implementation of EGFR mutation testing in routine clinical practice; 39 Spanish centres using two central testing centres and 7 on-site testing facilities newly acquired, archive tissue or either Tao 2011 Conference abstract Canada EGFR mutation testing in advanced NSCLC Result from pilot routine testing network NSCLC involving 5 testing laboratories 1869 requests March 2010 – Nov 2010 Not specified Reviewed, archive FFPE includes tissue and cytology samples Test failures TATRS TATRR Leary 2012 Full journal article UK EGFR mutation testing in advanced NSCLC Study of the feasibility of prospective EGFR testing in routine clinical practice; single testing centre Year 1: 152 samples (144 cases) Year 2: 755 cases Screening period: Jan 2009 - Jan 2010; Jan 2010 - Jan 2011 Year 1: TheraScreen EGFR29 ARMS mutation kit; Year 2: Combination of ARMS; fragment analysis; direct sequencing Blocks or slides; not specified whether testing was on newly acquired, archive tissue or either; some samples were from external sources Test failures TATO TATRS 2012 Conference abstract US EGFR and ALK mutation testing in NSCLC Retrospective observation study to determine the utility of a reflex testing policy for the mutations: 63 prior to policy; 123 post 6 months before and 6 months after introduction of reflex policy Not specified FFPE archival tissue used TATO
1331-Contracted_Assessment_Report-accessible.docx